drugset / Trial / NCT02845882

Summary

The outcomes of children with lymphoblastic lymphoma (LBL) in China in the investigators' previous study were not unexpected. In this study, through further modification treatment protocols and strengthen domestic multicenter collaboration, the investigators try to improve survival for children with LBL when compared to the previous study.

Timeline

Start
2016-01
Primary completion
2023-12-31
Completion
2031-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 200 mg/m2
Subject Cyclophosphamide Other / unclassified 1000 mg/m2
Subject Cytarabine Small molecule 75 mg/m2
Subject Cytarabine Small molecule 2000 mg/m2
Subject Daunorubicin Small molecule 25 mg/m2
Subject Daunorubicin Small molecule 30 mg/m2
Subject Dexamethasone Small molecule 10 mg/m2
Subject Dexamethasone Small molecule 20 mg/m2
Subject Doxorubicin Other / unclassified 30 mg/m2
Subject Etoposide Small molecule 100 mg/m2
Subject Ifosfamide Small molecule 800 mg/m2
Subject MERCAPTOPURINE ANHYDROUS Small molecule 25 mg/m2
Subject MERCAPTOPURINE ANHYDROUS Small molecule 50 mg/m2
Subject MERCAPTOPURINE ANHYDROUS Small molecule 60 mg/m2
Subject Methotrexate Small molecule 20 mg/m2
Subject Methotrexate Small molecule 5 g
Subject Methotrexate Small molecule 5000 mg/m2
Subject Pegylated asparaginase Unknown 2000 unknown
Subject Prednisone Other / unclassified 60 mg/m2
Subject Vincristine Small molecule 1.5 mg/m2
Subject Vindesine Small molecule 3 mg/m2